Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 16, 2004. The report details a share repurchase transaction executed on June 15, 2004, authorized by shareholders at the Annual General Meeting held on May 17, 2004.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the specific share buyback transaction:
- Shares Purchased: 1,200,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,134.11 pence per share.
- Treasury Holdings Post-Transaction: 21,699,000 shares.
- Shares in Issue (excluding Treasury): 5,911,892,457 shares.
Material Changes
The material change reported is the reduction of outstanding shares through the acquisition of 1,200,000 shares for Treasury. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies beyond the standard disclaimer that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the repurchase (1,200,000 shares x 1,134.11 pence).
- Confirm the updated total share count and Treasury holdings in subsequent filings.
- Review the Annual General Meeting minutes from May 17, 2004, for the full scope of the share buyback authority granted.